Patent SG-11201905528X-A (SG)
Title: A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease
Inventor: ACHOUR MILOUD
IPC: A61K31/5377
Filed: 2018-01-18
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIP0 I PCT omit VIII °nolo offilmomiloollowo oimIE (10) International Publication Number WO 2018/134760 Al (51) International Patent Classification: A61K 9/16 (2006.01) A61K 31/5377 (2006.01) A61K 9/48 (2006.01) A61P 25/28 (2006.01) A61K 9/14 (2006.01) (21) International Application Number: PCT/IB2018/050312 (22) International Filing Date: 18 January 2018 (18.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17152481.2 20 January 2017 (20.01.2017) EP (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). (72) Inventors: ACHOUR, Miloud; Novartis Pharma AG, Postfach, 4002 Basel (CH). GALLI, Bruno; Novartis Phar- ma AG, Postfach, 4002 Basel (CH). JOHN, Edgar; No- vartis Pharma AG, Postfach, 4002 Basel (CH). JUHNKE, Michael; Novartis Pharma AG, Postfach, 4002 Basel (CH). KNEZIC, Dragutin; 80 Hope Avenue, Apt 112, Waltham, Massachusetts 02453 (US). KORADIA, Vishal Shamji; Novartis Pharma AG, Postfach, 4002 Basel (CH). RAMOS, Rita; Novartis Pharma AG, Postfach, 4002 Basel (CH). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 00 (54) Title: A PHARMACEUTICAL COMPOSITION COMPRISING AN OXAZINE DERIVATIVE AND ITS USE IN THE TREAT- MENT OR PREVENTION OF ALZHEIMER'S DISEASE \" (57) : The present invention relates to a pharmaceutical composition comprising an oxazine derivative BACE-1 inhibitor, a 0 process for the preparation thereof, and its use in the treatment or prevention of Alzheimer's disease.